| | Study | Number of participants (T/C ) | Sex
(females/total) | TNM stage | CHM or CHM formula | Intervention in control group | Outcome assessment | OS (months) or 1-year SR (%) | Duration (week) | Jadad score |
| | Lu et al. 2014 [23] | 54 (27/27) | 23/57 | III-IV | Shenqi Fuzhen
injection | Gemcitabine injection,
Tegafur Gimeracil potassium capsule | OS, AEs, and symptoms | 10.7 | 6 | 2 |
| | Zhang et al. 2010 [24] | 32 (16/16) | 13/32 | II–IV | Xihuang pill | Gemcitabine injection | ORR, DCR, QOL, AEs, and symptoms | NR | 6 | 2 |
| | You and Yao 2009 [25] | 40 (20/20) | 17/40 | III-IV | Fuzhen Hewei
decoction | Gemcitabine and oxaliplatin injection | ORR, DCR, QOL, symptoms,
and laboratory values | NR | 8 | 2 |
| | Dong 2014 [26] | 68 (34/34) | 33/68 | II–IV | Qingyi decoction | Docetaxel and cisplatin
injection | ORR, DCR, 1- and 3-year SR,
symptoms, APACHE II score, and AEs | 52.94% | 6 | 2 |
| | Li 2014 [27] | 28 (17/11) | 12/28 | III-IV | Chanchu injection | Gemcitabine injection,
radiotherapy | ORR, DCR, and AEs | NR | 16–24 | 2 |
| | Wei et al. 2006 [28] | 42 (21/21) | 13/42 | III-IV | Ejiao paste | Gemcitabine, leucovorin, calcium, and fluorouracil
injection | ORR, DCR, 1-year SR, CBR, and AEs | 4.8% | 12 | 2 |
| | Li et al. 2009 [29] | 86 (51/35) | none | III-IV | Fuzhenkangai
decoction | Leucovorin, calcium, VP-16
cisplatin, and fluorouracil
injection | ORR, DCR, QOL, and AEs | 9 | 9 | 1 |
| | Chen 2012 [30] | 66 (36/30) | 31/66 | AS | Compound Kushen injection | Radiotherapy | ORR, DCR, QOL, and AEs | NR | 6 | 1 |
| | Dai 2014 [31] | 50 (25/25) | 23/50 | III-IV | Jiedu Huayu
Tongfu granules | Gemcitabine injection | ORR, DCR, AEs, symptoms,
and laboratory values | NR | 12 | 2 |
| | Zhang 2009 [32] | 63 (32/31) | 25/63 | III-IV | Compound Kushen injection | Gamma knife radiosurgery | ORR, DCR, AEs, QOL, CBR, and
laboratory values | NR | 3 | 2 |
| | Liu et al. 2014 [33] | 106 (58/48) | 36/106 | II–IV | Yiqi Huoxue
decoction | Radiotherapy, gemcitabine
injection | 1 and 2-year SR, ORR, DCR, AEs, and QOL | 75.3% | 6-7 | 1 |
| | Zhu et al. 2013 [34] | 55 (28/27) | 24/55 | AS | Kanglaite injection | γ-SBRT | ORR, AEs, and QOL | NR | 6 | 1 |
| | Shan et al. 2007 [35] | 65 (31/34) | | AS | Kanglaite injection | Fluorouracil and cisplatin
injection | ORR, QOL, and AEs | NR | 12 | 1 |
|
Zhu et al.
2013 [21] | 70 (35/35) | 25/70 | III-IV | Qinre Huaji
decoction | HAI/TACE | 1/2- and 1-year SR, ORR, QOL, and AEs | 31.43% | 16 | 3 |
| | Ni et al. 2013 [36] | 40 (19/21) | 17/40 | II–IV | WD-3 decoction | Gemcitabine, leucovorin,
calcium, and fluorouracil
injection | ORR, DCR, CBR, QOL, AEs,
symptoms, and laboratory values | NR | 8 | 2 |
| | Ma et al. 2012 [37] | 64 (32/32) | 13/64 | AS | Kanglaite injection | Gemcitabine injection | ORR, DCR, and AEs | NR | 24 | 1 |
| | Han et al. 2012 [38] | 65 (31/34) | NR | III-IV | Modified Sinisan
decoction | TAI
| ORR, AEs, QOL, and symptoms | NR | 8 | 3 |
| | Tian et al. 2012 [22] | 60 (30/30) | 32/60 | III-IV | Qingre Jiedu and
Huoxue Huayu
decoction | Gemcitabine injection | ORR, DCR, CBR, AEs, and laboratory values | NR | 8 | 2 |
| | Shen et al. 2010 [39] | 80 (41/39) | 30/80 | III-IV | Qingyi Huaji
formula | TAC + 3DCRT | ORR, 1/2-, 1-, 2-, and 3-year SR, OS, CBR, QOL, AEs, and symptoms | 9.8% | 8 | 2 |
| | Zhang et al. 2010 [40] | 136 (68/68) | 55/136 | AS | Qingyi Huaji
decoction | TAC + 3DCRT | 1/2- and 1-year SR, QOL, and AEs | 16.2% | NR | 1 |
| | Wang et al. 2013 [41] | 46 (23/23) | 21/46 | AS | Kangai injection | SBRT | ORR, QOL, AEs, and symptoms | NR | 3 | 2 |
| | S. M. Suo and X. H. Suo 2009 [42] | 39 (21/8) | 8/39 | AS | Yiqi Huoxue
decoction | Radiotherapy, TAI | ORR, 1- and 2-year SR, AEs, and
symptoms | 82.1% | NR | 1 |
| | Yang et al. 2014 [43] | 50 (30/20) | 22/50 | NR | Compound Kushen injection | Gemcitabine and oxaliplatin injection | DCR, QOL, and CBR | NR | 6–18 | 1 |
| | Yin et al. 2004 [44] | 76 (38/38) | 28/76 | NR | Jinlong capsule | Gamma knife radiosurgery | ORR, CBR, QOL, and AEs | NR | 13 | 2 |
| Wang et al. 2000 [45]
| 58 (30/28) | 15/58 | II-III | Yiqi Huoxue
decoction | Radiotherapy, TAC | 1- and 2-year rate, ORR, symptoms, and AEs | 80% | NR | 2 |
| | Gansauge et al. 2002 [19] | 60 (30/30) | 19/60 | III-IV | NSC-631570 | Gemcitabine injection | ORR, DCR, 1/2-, 2/3-, and 1-year SR, AEs, and QOL | 32% | 12 | 2 |
| | Meng et al. 2012 [20] | 76 (39/37) | 30/76 | NR | Huachansu injection | Gemcitabine injection | ORR, OS, TTP, symptoms, AEs, and 1/2-year SR | 5.3 | 8 | 3 |
| Chen et al. 2005 [46]
| 81 (41/40) | 36/81 | III-IV | Compound Danshen dripping pills | Gemcitabine and cisplatin
injection | ORR, DCR, QOL, AEs, and laboratory values | NR | 8 | 1 |
| | Dou 2010 [47] | 52 (26/26) | 27/52 | III-IV | Kangai injection | Gemcitabine and cisplatin
injection | ORR, CBR, and AEs | NR | 8 | 1 |
|
|
